L

Lavipharm SA
XBER:BXA

Watchlist Manager
Lavipharm SA
XBER:BXA
Watchlist
Price: 0.468 EUR 1.3% Market Closed
Market Cap: 23.9m EUR

Operating Margin
Lavipharm SA

11.5%
Current
10%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.5%
=
Operating Profit
6.1m
/
Revenue
53.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
GR
Lavipharm SA
ATHEX:LAVI
164.5m EUR
12%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
493.1B USD
27%
CH
Roche Holding AG
SIX:ROG
271.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
217.1B GBP
24%
US
Merck & Co Inc
NYSE:MRK
273.3B USD
38%
CH
Novartis AG
SIX:NOVN
217.8B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
145B USD
29%
No Stocks Found

Lavipharm SA
Glance View

Market Cap
23.9m EUR
Industry
Pharmaceuticals

Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

BXA Intrinsic Value
0.315 EUR
Overvaluation 33%
Intrinsic Value
Price
L
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.5%
=
Operating Profit
6.1m
/
Revenue
53.3m
What is the Operating Margin of Lavipharm SA?

Based on Lavipharm SA's most recent financial statements, the company has Operating Margin of 11.5%.

Back to Top